Dual Opioid and Alpha-2 Adrenergic Receptor Blockade Prevents Respiratory Depression from Fentanyl–Xylazine and Fentanyl-Dexmedetomidine Exposure

Overdoses with illicit drugs remain the leading cause of death among adolescents and adults aged 18-44 across the United States. Fentanyl is the primary contributor to these overdoses, and naloxone, an opioid receptor antagonist, is used to reverse the opioid-induced respiratory depression. However, drug adulteration is constantly evolving in the illicit supply. Recently, the addition of xylazine and/or medetomidine, both alpha-2 adrenergic receptor agonists that do not respond to naloxone, has increased fatal overdoses. Medetomidine is the racemic mixture, and dexmedetomidine is the pharmacologically active isomer responsible for its sedative and analgesic effects. The mechanism by which the combination of fentanyl and xylazine or dexmedetomidine exacerbates the effects on respiration is unknown. Therefore, we want to determine if the respiratory-depressant effects of fentanyl-xylazine and fentanyl-dexmedetomidine are blocked by dual opioid receptor and alpha-2 receptor antagonism. Male (N=2-6) and female (N=2-6) Sprague-Dawley rats (250-300 grams) were implanted with intrajugular catheters at Charles River Laboratories and arrived at our vivarium two weeks after recovery. We examined the respiratory effects of the combination of opioids and alpha-2 adrenergic receptor agonists in two studies. Study 1) fentanyl (0.04 mg/kg) + xylazine (1 mg/kg) (FX) after a pre-treatment of naloxone (0.2 mg/kg) + atipamezole (1 mg/kg) (NA) or saline alone (0.9 % NaCl); Study 2) fentanyl (0.04 mg/kg) + dexmedetomidine (0.03 mg/kg) after a pre-treatment of NA or saline alone. Data were obtained in freely moving rats using a Buxco/DSI whole-body plethysmography system. Animals were acclimated to the chambers for three consecutive days a week, with weekly drug administration immediately after the third day of acclimation. Study 1 showed that treatment produced robust effects across all respiratory parameters, with significant main effects of drug on respiratory rate, expiratory time, inspiratory time, and minute volume (p < 0.0001). Even with a main effect of sex on all respiratory parameters, pre-treatment with NA prevented the respiratory depressant effect of FX in both sexes. Interestingly, females exhibit a greater increase in respiratory rate (interaction, p = 0.007) and a greater reduction in expiratory time (interaction, p < 0.0001) in response to NA, indicating that females are more sensitive to this treatment. We also found a strong main effect of the drug in study 2, showing differences in respiratory rate, expiratory time, minute volume, inspiratory time (p < 0.0001), and tidal volume (p=0.003). Females exhibit a greater increase in respiratory rate (interaction, p = 0.004) and a greater reduction in inspiratory time (interaction, p < 0.001) in response to NA. This indicates that females presented a stronger respiratory response, suggesting greater sensitivity to this drug combination. Administration of NA blocks opioid and alpha-2 adrenergic receptors, preventing respiratory depression caused by the administration of FX or FD. The safety and efficacy of atipamezole in humans remain largely untested and require further investigation. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.